MoonLake Immunotherapeutics (MLTX)
46.76
+0.34
(+0.73%)
USD |
NASDAQ |
Nov 01, 16:00
46.48
-0.28
(-0.60%)
After-Hours: 20:00
MoonLake Immunotherapeutics PE Ratio
PE Ratio Chart
Historical PE Ratio Data
| Date | Value |
|---|---|
| November 01, 2024 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Novartis AG | 12.82 |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -- |
| Addex Therapeutics Ltd | -- |
| NLS Pharmaceutics Ltd | -- |
PE Ratio Related Metrics
| Price to Book Value | 5.648 |
| Price | 46.76 |
| Earnings Yield | -1.90% |
| Market Cap | 2.941B |